You can buy or sell EVLO and other stocks, options, and ETFs commission-free!
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA. The listed name for EVLO is Evelo Biosciences, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Feb 11, Pre-Market